Streptococcus pneumoniae-induced regulation of cyclooxygenase-2 in human lung tissue

The majority of cases of community-acquired pneumonia are caused by Streptococcus pneumoniae and most studies on pneumococcal host interaction are based on cell culture or animal experiments. Thus, little is known about infections in human lung tissue. Cyclooxygenase-2 and its metabolites play an important regulatory role in lung inflammation. Therefore, we established a pneumococcal infection model on human lung tissue demonstrating mitogen-activated protein kinase (MAPK)-dependent induction of cyclooxygenase-2 and its related metabolites. In addition to alveolar macrophages and the vascular endothelium, cyclooxygenase-2 was upregulated in alveolar type II but not type I epithelial cells, which was confirmed in lungs of patients suffering from acute pneumonia. Moreover, we demonstrated the expression profile of all four E prostanoid receptors at the mRNA level and showed functionality of the E prostanoid4 receptor by cyclic adenosine monophosphate production. Additionally, in comparison to previous studies, cyclooxygenase-2/prostaglandin E2 related pro- and anti-inflammatory mediator regulation was partly confirmed in human lung tissue after pneumococcal infection. Overall, cell type-specific and MAPK-dependent cyclooxygenase-2 expression and prostaglandin E2 formation in human lung tissue may play an important role in the early phase of pneumococcal infections.

[1]  D. Musher,et al.  Community-acquired pneumonia. , 1995, The New England journal of medicine.

[2]  K. Weylandt,et al.  Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. , 2011, Prostaglandins & other lipid mediators.

[3]  D. Aronoff,et al.  E-Prostanoid 3 Receptor Deletion Improves Pulmonary Host Defense and Protects Mice from Death in Severe Streptococcus pneumoniae Infection1 , 2009, The Journal of Immunology.

[4]  T. Hartung.  Thoughts on limitations of animal models. , 2008, Parkinsonism & related disorders.

[5]  T. Goldmann,et al.  Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. , 2008, American journal of respiratory cell and molecular biology.

[6]  N. Suttorp,et al.  Subcellular expression pattern and role of IL-15 in pneumococci induced lung epithelial apoptosis , 2008, Histochemistry and Cell Biology.

[7]  S. Skerrett,et al.  Animal models of human pneumonia. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[8]  J. Christman,et al.  Conditional regulation of cyclooxygenase‐2 in tracheobronchial epithelial cells modulates pulmonary immunity , 2007, Clinical and experimental immunology.

[9]  N. Suttorp,et al.  Moraxella catarrhalis induces ERK- and NF-κB-dependent COX-2 and prostaglandin E2 in lung epithelium , 2007, European Respiratory Journal.

[10]  I. Dougall,et al.  Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages , 2007, European Respiratory Journal.

[11]  H. Mollenkopf,et al.  Cell-specific interleukin-15 and interleukin-15 receptor subunit expression and regulation in pneumococcal pneumonia--comparison to chlamydial lung infection. , 2007, Cytokine.

[12]  J. Christman,et al.  Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX‐2 , 2007, European journal of immunology.

[13]  N. Suttorp,et al.  Legionella pneumophila-induced PKCalpha-, MAPK-, and NF-kappaB-dependent COX-2 expression in human lung epithelium. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[14]  Thomas Hartung,et al.  Food for thought... on cell culture. , 2007, ALTEX.

[15]  W. Schaffner,et al.  Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study , 2006, The Lancet.

[16]  N. Suttorp,et al.  Streptococcus pneumoniae induced c-Jun-N-terminal kinase- and AP-1 -dependent IL-8 release by lung epithelial BEAS-2B cells , 2006, Respiratory research.

[17]  N. Suttorp,et al.  Streptococcus pneumoniae induced p38 MAPK- and NF-kappaB-dependent COX-2 expression in human lung epithelium. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[18]  J. Christman,et al.  Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[19]  N. Suttorp,et al.  Streptococcus Pneumoniae-induced P38 MAPK and NF-kB dependent COX-2 expression in human lung epithelium , 2006 .

[20]  N. Suttorp,et al.  Legionella pneumophila-induced PKC, P38 MAPK and NF-kB dependent COX-2 expression in human lung epithelium , 2006 .

[21]  K. Kirtikara,et al.  Positive feedback regulation of COX-2 expression by prostaglandin metabolites , 2005, Inflammation Research.

[22]  N. Suttorp,et al.  Differences in Cell Activation by Chlamydophila pneumoniae and Chlamydia trachomatis Infection in Human Endothelial Cells , 2004, Infection and Immunity.

[23]  N. Suttorp,et al.  Streptococcus pneumoniae-Induced Caspase 6-Dependent Apoptosis in Lung Epithelium , 2004, Infection and Immunity.

[24]  C. Vancheri,et al.  The lung as a privileged site for the beneficial actions of PGE2. , 2004, Trends in immunology.

[25]  J. Hodgson,et al.  Measurement of 20-hydroxyeicosatetraenoic acid in human urine by gas chromatography-mass spectrometry. , 2004, Clinical chemistry.

[26]  T. Horie,et al.  Role of mitogen‐activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  Y. Sugimoto,et al.  Contribution of the two Gs-coupled PGE2-receptors EP2-receptor and EP4-receptor to the inhibition by PGE2 of the LPS-induced TNFalpha-formation in Kupffer cells from EP2-or EP4-receptor-deficient mice. Pivotal role for the EP4-receptor in wild type Kupffer cells. , 2002, Journal of hepatology.

[28]  A. Mistretta,et al.  Normal human lung fibroblasts differently modulate interleukin-10 and interleukin-12 production by monocytes: implications for an altered immune response in pulmonary chronic inflammation. , 2001, American journal of respiratory cell and molecular biology.

[29]  R. Langenbach,et al.  Why there are two cyclooxygenase isozymes. , 2001, The Journal of clinical investigation.

[30]  M. Yacoub,et al.  Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy. , 2001, American journal of respiratory cell and molecular biology.

[31]  M. Yacoub,et al.  Effects of Prostaglandin E2 and cAMP Elevating Drugs on GM-CSF Release by Cultured Human Airway Smooth Muscle Cells , 2001 .

[32]  R. Finch.  Community-acquired pneumonia: the evolving challenge. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[34]  D. Trajkovic,et al.  Cyclooxygenase-2 Expression in Inflammatory Lung Lesions of Nonhuman Primates , 2000, Veterinary pathology.

[35]  L. Zhang,et al.  Prostaglandin-E2 counteracts interleukin-1beta-stimulated upregulation of platelet-derived growth factor alpha-receptor on rat pulmonary myofibroblasts. , 1999, American journal of respiratory cell and molecular biology.

[36]  Sheldon P Stone,et al.  Community-acquired pneumonia , 1998, The Lancet.

[37]  N. Suttorp,et al.  Interaction of human neutrophils with airway epithelial cells: Reduction of leukotriene B4 generation by epithelial cell derived prostaglandin E2 , 1998, Journal of cellular physiology.

[38]  V. Dimmer,et al.  Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis , 1997, Histochemistry and Cell Biology.

[39]  R. Moellering,et al.  Antimicrobial-drug resistance. , 1996, The New England journal of medicine.